Why is the dual receptor agonist tirzepatide (Mounjaro, Zepbound) more potent than semaglutide (Ozempic, single receptor, GLP-1 agonist)?
www.cell.com/cell-reports...
www.cell.com/cell-reports...
Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy
Rodriguez et al. investigate the impact of biased signaling with a dual GLP-1R/GIPR
agonist. Biased GLP-1R and GIPR agonism leads to better and prolonged glucose lowering,
greater food intake reductio...
www.cell.com
June 2, 2025 at 3:10 PM
Why is the dual receptor agonist tirzepatide (Mounjaro, Zepbound) more potent than semaglutide (Ozempic, single receptor, GLP-1 agonist)?
www.cell.com/cell-reports...
www.cell.com/cell-reports...
So how come GIPR antagonists and GIPR agonists *both* lead to lower food intake and weight loss? Two new papers shed some light:
GIPR: Agonists and Antagonists Do the Same Thing, But How
www.science.org
May 8, 2025 at 7:29 PM
So how come GIPR antagonists and GIPR agonists *both* lead to lower food intake and weight loss? Two new papers shed some light:
This time we found variants in both GLP1R and GIPR associated with nausea and vomiting. Interestingly, the GIPR association was specific to patients taking tirzepatide (aka Mounjaro or Zepbound)... this also makes sense; tirzepatide targets both GLP1R and GIPR!
April 8, 2026 at 3:42 PM
This time we found variants in both GLP1R and GIPR associated with nausea and vomiting. Interestingly, the GIPR association was specific to patients taking tirzepatide (aka Mounjaro or Zepbound)... this also makes sense; tirzepatide targets both GLP1R and GIPR!
Boss (JPN/PAL) - Sonic the Hedgehog CD Music Extended
YouTube video by HyperSonic
www.youtube.com
December 30, 2025 at 6:46 AM
Expanding metabolic roles for the GIPR in oligodendrocytes #weightloss www.cell.com/cell-metabol...
Glucose-dependent insulinotropic polypeptide receptor signaling in oligodendrocytes increases the weight-loss action of GLP-1R agonism
Hansford et al. show that GIPR, a target of new weight-loss drugs, is found in brain
cells called oligodendrocytes. GIPR helps these drugs access the brain and boosts
weight loss. Without GIPR in thes...
www.cell.com
August 14, 2025 at 3:07 PM
Expanding metabolic roles for the GIPR in oligodendrocytes #weightloss www.cell.com/cell-metabol...
Nature research paper: GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice
go.nature.com/4tR7wir
go.nature.com/4tR7wir
GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice - Nature
GLP-1–GIP–lanifibranor, a single-molecule agonist of GLP-1R, GIPR, PPARα, PPARγ and PPARδ, shows promising therapeutic efficacy against obesity-linked metabolic dysfunction in vitro and in mouse models via synergistic incretin and PPAR activity.
go.nature.com
April 29, 2026 at 5:01 PM
Nature research paper: GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice
go.nature.com/4tR7wir
go.nature.com/4tR7wir
[ainet] [인실리코, 차세대 비만 치료제로 AI 설계 GIPR 차단제 ISM1354 지명] 인실리코의 창립자이자 공동 CEO인 알렉스 자보론코프 박사는 이 사안이 어디로 향하고 있는지에 대해 직설적으로 말한다.
www.ainet.link/29047
www.ainet.link/29047
[인실리코, 차세대 비만 치료제로 AI 설계 GIPR 차단제 'ISM1354' 지명] 인실리코의 창립자이자 공동 CEO인 알렉스 자보론코프 박사는 이 사안이 어디로 향하고 있는지에 대해 직설적으로 말한다.
인실리코,차세대비만치료제로AI설계GIPR차단제'ISM1354'지명 초기동물·실험실데이터서경쟁화합물대비최소18배혈중노출…더넓은안전마진AI신약개발사
www.ainet.link
October 2, 2026 at 2:25 PM
[ainet] [인실리코, 차세대 비만 치료제로 AI 설계 GIPR 차단제 ISM1354 지명] 인실리코의 창립자이자 공동 CEO인 알렉스 자보론코프 박사는 이 사안이 어디로 향하고 있는지에 대해 직설적으로 말한다.
www.ainet.link/29047
www.ainet.link/29047
Genetic variants in GLP1R and GIPR, which encode targets of GLP-1-based medications, offer insights into why responses to these drugs vary and who might face adverse effects
go.nature.com/4vBzAYy
go.nature.com/4vBzAYy
Genetics reveal why people respond differently to GLP-1 weight-loss drugs
Genetic variants in GLP1R and GIPR, which encode targets of GLP-1-based medications, offer insights into why responses to these drugs vary and who might face adverse effects.
go.nature.com
April 13, 2026 at 1:04 PM
Genetic variants in GLP1R and GIPR, which encode targets of GLP-1-based medications, offer insights into why responses to these drugs vary and who might face adverse effects
go.nature.com/4vBzAYy
go.nature.com/4vBzAYy
Really excited to share our new bioRxiv preprint! 🎉
www.biorxiv.org/content/10.6...
In this study, we dissect the roles of GIPR neurons in two adjacent brainstem nuclei, the area postrema (AP) and nucleus tractus solitarius (NTS), and show that they have opposing effects on feeding.
www.biorxiv.org/content/10.6...
In this study, we dissect the roles of GIPR neurons in two adjacent brainstem nuclei, the area postrema (AP) and nucleus tractus solitarius (NTS), and show that they have opposing effects on feeding.
Opposing GIPR brainstem circuits differentially control feeding behaviour
Central glucose-dependent insulinotropic polypeptide receptor (GIPR) signalling is required for the efficacy of GIP-based obesity therapeutics, yet how distinct subpopulations of GIPR neurons shape ap...
www.biorxiv.org
July 8, 2026 at 8:52 AM
Really excited to share our new bioRxiv preprint! 🎉
www.biorxiv.org/content/10.6...
In this study, we dissect the roles of GIPR neurons in two adjacent brainstem nuclei, the area postrema (AP) and nucleus tractus solitarius (NTS), and show that they have opposing effects on feeding.
www.biorxiv.org/content/10.6...
In this study, we dissect the roles of GIPR neurons in two adjacent brainstem nuclei, the area postrema (AP) and nucleus tractus solitarius (NTS), and show that they have opposing effects on feeding.
Here Liu, Veniant & colleagues discover that a maritide like bispecific GIPR antagonist/GLP-1R agonist antibody requires both CNS GLP-1R/ GIPR for maximal #weightloss revealing loss of CNS GIPR augments the CNS actions of GLP-1 #obesity @naturemetabolism.bsky.social
www.nature.com/articles/s42...
www.nature.com/articles/s42...
GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice - Nature Metabolism
This study, together with a companion manuscript, shows that in mice, weight loss as a result of GIP receptor antagonism requires and potentiates functional GLP-1 receptor signalling in the brain, exp...
www.nature.com
April 29, 2025 at 9:44 AM
Here Liu, Veniant & colleagues discover that a maritide like bispecific GIPR antagonist/GLP-1R agonist antibody requires both CNS GLP-1R/ GIPR for maximal #weightloss revealing loss of CNS GIPR augments the CNS actions of GLP-1 #obesity @naturemetabolism.bsky.social
www.nature.com/articles/s42...
www.nature.com/articles/s42...
With an editorial from the expert, Dr. Alice E. Adriaenssens
@cambridgeuni.bsky.social
disentangling divergent neural networks that explain the success of both GIPR gain and loss of function strategies for promoting #weightloss #obesity @naturemetabolism.bsky.social
www.nature.com/articles/s42...
@cambridgeuni.bsky.social
disentangling divergent neural networks that explain the success of both GIPR gain and loss of function strategies for promoting #weightloss #obesity @naturemetabolism.bsky.social
www.nature.com/articles/s42...
April 29, 2025 at 9:58 AM
With an editorial from the expert, Dr. Alice E. Adriaenssens
@cambridgeuni.bsky.social
disentangling divergent neural networks that explain the success of both GIPR gain and loss of function strategies for promoting #weightloss #obesity @naturemetabolism.bsky.social
www.nature.com/articles/s42...
@cambridgeuni.bsky.social
disentangling divergent neural networks that explain the success of both GIPR gain and loss of function strategies for promoting #weightloss #obesity @naturemetabolism.bsky.social
www.nature.com/articles/s42...
Our newest study looking at the impact of missense GIPR variants in BMI versus glycemia, receptor stability, and pancreatic islet function.
www.medrxiv.org/content/10.1...
A collaboration of Imperial College with Eli Lilly and University of Cambridge.
www.medrxiv.org/content/10.1...
A collaboration of Imperial College with Eli Lilly and University of Cambridge.
Glycaemic and bodyweight effects of GIPR coding variation reflect differences in both surface expression and intrinsic functional impairment
The glucose-dependent insulinotropic polypeptide receptor (GIPR) is the target of several approved and investigational drugs for type 2 diabetes and obesity. Missense coding variation in GIPR could co...
www.medrxiv.org
August 20, 2025 at 3:10 PM
Our newest study looking at the impact of missense GIPR variants in BMI versus glycemia, receptor stability, and pancreatic islet function.
www.medrxiv.org/content/10.1...
A collaboration of Imperial College with Eli Lilly and University of Cambridge.
www.medrxiv.org/content/10.1...
A collaboration of Imperial College with Eli Lilly and University of Cambridge.
The new portal adiposetissue.org enables another interrogation of localization of human GIPR expression from 3 different single cell WAT analyses. While there is some adipocyte GIPR expression, once again, the majority of GIPR expression is localized to non-adipocyte cell types adiposetissue.org
February 22, 2025 at 10:12 PM
The new portal adiposetissue.org enables another interrogation of localization of human GIPR expression from 3 different single cell WAT analyses. While there is some adipocyte GIPR expression, once again, the majority of GIPR expression is localized to non-adipocyte cell types adiposetissue.org
The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice 🧪
www.cell.com/cell-metabol...
www.cell.com/cell-metabol...
The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice
The functional role of peripheral GIPR action in weight loss is yet to be fully defined in a preclinical setting. Here, Yu et al. propose a mechanism whereby inducible activation of GIPR in adipocytes promotes energy wasting through futile calcium cycling, triggering profound weight loss in the obese state.
www.cell.com
December 5, 2024 at 4:46 PM
The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice 🧪
www.cell.com/cell-metabol...
www.cell.com/cell-metabol...
GIP receptor agonism suppresses inflammation-induced aversion and food intake via distinct circuits
GIP receptor agonism suppresses inflammation-induced aversion and food intake via distinct circuits
Province et al. show that parabrachial CGRP neurons mediate aversion due to interleukin-1β (IL-1β) administration. Glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism blocks aversion and CGRP activation caused by IL-1β while potentiating its anorectic effect. Dorsal vagal complex GIPR mediates anorexia due to GIPR agonism but may be dispensable for anti-aversion.
dlvr.it
April 3, 2026 at 2:38 PM
GIP receptor agonism suppresses inflammation-induced aversion and food intake via distinct circuits
Localization of the inflammation associated anti-aversive actions of GIPR agonism via sites distinct from those that suppress appetite in the DVC www.cell.com/cell-reports...
GIP receptor agonism suppresses inflammation-induced aversion and food intake via distinct circuits
Province et al. show that parabrachial CGRP neurons mediate aversion due to interleukin-1β
(IL-1β) administration. Glucose-dependent insulinotropic polypeptide receptor (GIPR)
agonism blocks aversion ...
www.cell.com
March 22, 2026 at 11:36 AM
Localization of the inflammation associated anti-aversive actions of GIPR agonism via sites distinct from those that suppress appetite in the DVC www.cell.com/cell-reports...
P2 #weightloss data over 13 weeks for VK2735 the once weekly GIPR-GLP1R medicine in adults with #obesity or overweight and ≥ 1 weight-related comorbidity onlinelibrary.wiley.com/doi/10.1002/...
January 10, 2026 at 12:29 PM
P2 #weightloss data over 13 weeks for VK2735 the once weekly GIPR-GLP1R medicine in adults with #obesity or overweight and ≥ 1 weight-related comorbidity onlinelibrary.wiley.com/doi/10.1002/...
Some new preclinical and clinical data for CT-388, a once weekly cAMP signal-biased dual GLP-1R/GIPR agonist with minimal GLP-1R/GIPR internalization #obesity #weightloss www.sciencedirect.com/science/arti... 🧪
Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity
Biased agonism of the glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptors (GLP-1R/GIPR) yields greater weight loss and bett…
www.sciencedirect.com
November 28, 2025 at 10:26 PM
Some new preclinical and clinical data for CT-388, a once weekly cAMP signal-biased dual GLP-1R/GIPR agonist with minimal GLP-1R/GIPR internalization #obesity #weightloss www.sciencedirect.com/science/arti... 🧪
Amid lots of uncertainty, anger, and exhaustion I am excited to share this work from my incredibly talented MSTP and @nuincomm.bsky.social student Haley Province. In it we explore the fascinating and powerful anti-aversive properties of GIPR agonists
GIP receptor agonism suppresses inflammation-induced aversion and food intake via distinct circuits https://www.biorxiv.org/content/10.1101/2025.08.12.669936v1
August 16, 2025 at 6:20 PM
Amid lots of uncertainty, anger, and exhaustion I am excited to share this work from my incredibly talented MSTP and @nuincomm.bsky.social student Haley Province. In it we explore the fascinating and powerful anti-aversive properties of GIPR agonists
GLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways
GLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways
Lindquist et al. show that GLP-1 and semaglutide, but not exendin 4 or GIP, selectively drive GLP-1R-GIPR heterodimerization, altering receptor trafficking and signaling. These findings uncover a mechanistic basis for incretin crosstalk and provide a structural framework for optimizing therapies for obesity and type 2 diabetes.
dlvr.it
September 17, 2026 at 9:01 PM
GLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways
Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy: Cell Reports Medicine www.cell.com/cell-reports...
Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy
Rodriguez et al. investigate the impact of biased signaling with a dual GLP-1R/GIPR
agonist. Biased GLP-1R and GIPR agonism leads to better and prolonged glucose lowering,
greater food intake reductio...
www.cell.com
June 5, 2025 at 11:17 PM
Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy: Cell Reports Medicine www.cell.com/cell-reports...
Our newest preprint about a new GLP-1R/GIPR dual agonist:
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Binding Kinetics, Bias, Receptor Internalization and Effects on Insulin Secretion in vitro and in vivo of a Novel GLP-1R/GIPR Dual Agonist, HISHS-2001
The use of incretin analogues has emerged in recent years as an effective approach to achieve both enhanced insulin secretion and weight loss in type 2 diabetes (T2D) patients. Agonists which bind and...
www.biorxiv.org
January 17, 2025 at 8:17 PM
Our newest preprint about a new GLP-1R/GIPR dual agonist:
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
how come they only report tirzepatide as a glp-1r agonist when gipr is also part of the picture 🧐 justice for my boy gipr
June 8, 2026 at 10:36 PM
how come they only report tirzepatide as a glp-1r agonist when gipr is also part of the picture 🧐 justice for my boy gipr
$GIPR — Generation Income Properties (GIPR) financial restructuring and volatile market indicators dominated recent analyses.
Strong short-term buying pressure indicated by Money Flow Index (MFI).
https://market-scanner.net/tickers/GIPR.US
#ai #trading
Strong short-term buying pressure indicated by Money Flow Index (MFI).
https://market-scanner.net/tickers/GIPR.US
#ai #trading
GIPR.US — AI analysis summary
Descriptive, non-directional summary of recent AI analyses.
market-scanner.net
October 2, 2026 at 12:36 PM
$GIPR — Generation Income Properties (GIPR) financial restructuring and volatile market indicators dominated recent analyses.
Strong short-term buying pressure indicated by Money Flow Index (MFI).
https://market-scanner.net/tickers/GIPR.US
#ai #trading
Strong short-term buying pressure indicated by Money Flow Index (MFI).
https://market-scanner.net/tickers/GIPR.US
#ai #trading